Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service？ Thank you for choosing ACROBiosystems. Would you rate our product and service？
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
FACS assay shows that Anti-CCR5 antibody can bind to HEK293/Human CCR5 Stable Cell Line. HEK293/Human CCR5 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).
Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) captured on CM5 chip via anti-His antibody can bind Anti-CCR5 antibody (Human IgG1) with an affinity constant of 0.0737 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).
Purified NA/LE Mouse Anti-Human CD195 (Clone: 2D7) (Mouse IgG2a) captured on CM5 chip via anti-mouse antibodies surface can bind Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) with an affinity constant of 7.51 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Maraviroc | MVC; UK-427857 | Approved | Viiv Healthcare | Celsentri, Selzentry | Mainland China | HIV Infections | Godecke Gmbh | 2007-08-06 | HIV Infections; Hypertriglyceridemia; Acquired Immunodeficiency Syndrome; Hematopoietic stem cell transplantation (HSCT); Hematologic Neoplasms; Kidney Diseases; Arthritis, Rheumatoid; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Stroke; AIDS Dementia Complex; Cardiovascular Diseases; Inflammation; Sarcoma, Kaposi | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| BMS-687681 | BMS-687681 | Phase 1 Clinical | Neoplasms | Details | |
| Cenicriviroc mesylate/Tropifexor | LJC-242 | Phase 2 Clinical | Novartis Pharma Ag | Non-alcoholic Fatty Liver Disease | Details |
| Thioraviroc | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | HIV Infections | Details | |
| Anti-CCR5 monoclonal antibody (Human Genome Sciences) | HGS-1025 | Glaxosmithkline Plc | Details | ||
| PF-04634817 | PF-4634817; PF-04634817; PF-46334817 | Pfizer Pharmaceuticals Ltd (China) | Details | ||
| INCB-009471 | INCB-9471; INCB-009471 | Incyte Corp | Details | ||
| AZD-5672 | AZD5672; AZD-5672 | Astrazeneca Plc | Details | ||
| AGT 103-T | AGT 103-T | American Gene Technologies International Inc | Details | ||
| Lamivudine/Maraviroc/Zidovudine | GSK-2838510 | Glaxosmithkline Plc | Details | ||
| BMS-813160 | BMS-813160 | Phase 2 Clinical | Bristol-Myers Squibb Company | Pancreatic Neoplasms; Hyperplasia; Diabetic Nephropathies; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular | Details |
| SB-728-HSC | SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC | Phase 1 Clinical | Sangamo Biosciences | HIV Infections | Details |
| Vicriviroc | SCH-D; MK-4176; SCH-417; Sch-417690 | Phase 2 Clinical | Merck & Co Inc | HIV Infections; Acquired Immunodeficiency Syndrome; Colorectal Neoplasms | Details |
| SB-728-T | SB-728mR-T; SB-728-T | Phase 2 Clinical | Sangamo Biosciences | HIV Infections | Details |
| Cenicriviroc mesylate | CCR5/CCR2 antagonist; TBR-652; CVC; TAK-652 | Phase 3 Clinical | Tobira Therapeutics Inc, Takeda Pharmaceutical Co Ltd | Prediabetic State; HIV Infections; Acquired Immunodeficiency Syndrome; Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Liver Cirrhosis; Coronavirus Disease 2019 (COVID-19); AIDS Dementia Complex; Cholangitis, Sclerosing; Hepatic Insufficiency; Obesity; Cognition Disorders | Details |
| Leronlimab | PRO-140; PA-14; HuPRO-140 | Phase 3 Clinical | Cytodyn Inc | HIV Infections; Solid tumours; Non-alcoholic Fatty Liver Disease; Coronavirus Disease 2019 (COVID-19); Triple Negative Breast Neoplasms; Graft vs Host Disease | Details |
This web search service is supported by Google Inc.
アクロバイオシステムズの公式アカウント
A-Z
